RESEARCH GRANT

Research Grant

NO.	STUDY	PROTOCOL	SPONSOR	PI	CO-PI	TEAM STUDY	DURATION	STUDY LINK
	OnTARGET / TRANSCEND TRIALC6:C57	ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for CV Events.	PHRI & Mc Master University, Canada	Prof Dato’ Dr Khalid Yusoff			2004-2008	https://clinicaltrials.gov/ct2/show/NCT00153101
	SMARTER	Symbicort Maintenance and Reliver Therapy, Experience in Real Life Setting in Malaysia	Astra Zeneca	AP Dr Tengku Saifudin Tengku Ismail			2007-2009	https://clinicaltrials.gov/ct2/show/NCT00793624
	RESPIMART STUDY	A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess Long Term (1year) Efficacy and Safety of Tiotropium Inhalation Solution 5µg (2 puff of 2.5 µg) Delivered by the Respimart Inhaller in Patients in Chronic Obstructive Pulmonary Disease.	Boehringer Ingelheim	AP Dr Tengku Saifudin Tengku Ismail			2007-2009
	EPOCH Study	Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries.	PHRI & Mc Master University, Canada	Prof Dato’ Dr Khalid Yusoff		1) Mohd Yazrie Yacob 2) Mohd Khairul Azizi Ramli 3) Nurhafiza Zainon 4) Rasyidah Salleh 5) Siti Radziah Norlizan 6) Nurshamin bt Mohd Ghazali	2009 -2011	https://www.clinicaltrials.gov/ct2/show/NCT03225586
	COPD	A randomized, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 48 weeks of once daily treatment of orally inhaled BI 1744 CL (5µg [2 actuations of 2.5µg] and 10µg [2 actuations of 5µg]) delivered by Repimat Inhaler and 48 weeks of twice daily Foradil (12µg) delivered by the Aerolizer Inhaler in patients with Chronic Obstructive Pulmonary Disease	Boehringer Ingelheim	AP Dr Tengku Saifudin Tengku Ismail	Dr Wan Haniza		2009-2011	https://clinicaltrials.gov/ct2/show/NCT00793624
	ADOPT	A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of The Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Following Hospitalization (EC Reference number: NMRR-08-1034-2189)-Apixaban Dosing to Optimize Protection from Thrombosis	Bristol Mayer Squibb	Prof Dato’ Dr Khalid Yusoff	Dr. Effarezan Abdul Rahman		2009-2012	https://clinicaltrials.gov/ct2/show/NCT00457002
	RIVAROX – ACS3001@ ATLAS II	A Randomized, Double – blind, Event – Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subject With a Recent Acute Coronary Syndrome.	Johnson & Johnson Pharmaceutical Research & Development	Prof Dato’ Dr Khalid Yusoff	Dr. Effarezan Abdul Rahman		2010 – 2011	https://clinicaltrials.gov/ct2/show/NCT00809965
	ARISTOTLE	A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation	Bristol Mayer Squibb	Prof Dato’ Dr Khalid Yusoff	1)Dr. Mohd Kamal Mohd Arshad 2)Assoc Prof Dr. Tengku Saifuddin Tengku Ismail		2007-2012	https://clinicaltrials.gov/ct2/show/NCT00412984
	SAKURA	A Comparison of Symbicort Maintenance and Reliver Therapy (Symbicort Turbuhaler 160/4.5 µg, one inhalation bid plus as needed) and Symbicort Turbuhaler 160/4.5µg, one inhalation bid plus terbutaline Turbuhaler 0.4mg/inhalation as needed, for treatment of asthma - a 12 month, randomized, double-blind, parallel group, active - controlled, multinational phase III study in asthmatic patients aged 16 years and above.	Astra Zeneca	Assoc Prof Dr Tengku Saifudin	1)Dr Wan Haniza 2)Dr Annamalai Chandra mouli		2009-2012	https://clinicaltrials.gov/ct2/show/NCT00839800
	TIOSPIR	A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 mg and 5μg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler with Tiotropium Inhalation Capsules 18μg Delivered by the Handihaler	Boehringer Ingelhem	AP Dr Tengku Saifudin Tengku Ismail	1)Dr Wan Haniza 2)Dr Ahmad Izuanuddin 3)Dr Mohd Arif Mohd Zim		2010-2012	https://clinicaltrials.gov/ct2/show/NCT01126437
	SYR322_402 @ EXAMINE TRIAL	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome	TAKEDA Global Research and Development	Prof Dato’ Dr Khalid Yusoff	Dr. Effarezan Abdul Rahman		2010-2014	https://clinicaltrials.gov/ct2/show/NCT00968708
	APOLLO	A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People - Aliskiren Prevention Of Later Life Outcomes	PHRI & Novartis	Prof Dato’ Dr Khalid Yusoff	1)Dr. Effarezan Abdul Rahman 2)Dr. Mohd Kamal Mohd Arshad 3)Dr.Mazapuspavina Mat Yasin 4)Dr. Maizatullifah Miskan 5)Dr. Ambigga Devi S. Krishnapilai 6)Dr. Ng Kien Keat 7)Dr. Farnaza Ariffin 8)Dr. Marymol Koshy		2011-2012	https://www.phri.ca/research/apollo
	ALEPREVENT	Phase 3B Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with Stable CVD and Glucose Abnormalities	F. Hoffman-La Roche	Prof Dato’ Dr Khalid Yusoff	1)Assoc Prof Dr Sazzli Sahlan Kasim 2)Dr. Mohd Kamal Mohd Arshad		2012-2013	https://clinicaltrials.gov/ct2/show/NCT01715818
	INTERSTROKE	Importance of Conventional and Emerging Risk Factors for Stroke in Different Regions of the World and in Different Ethnic Groups: A Case-control Study	PHRI & Mc Master University, Canada	Prof Dato’ Dr Khalid Yusoff	1)Dr. Annamalai Chandramouli 2)Dr Zubin Othman Ibrahim 3)Dr Andrian Husin	Sazreza Shahadan	2009-2014	https://www.phri.ca/research/interstroke
	ADVANCE-ON	A post-trial observational study extension to ADVANCE, a factorial randomized controlled trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release gliclazide (gliclazide MR)-based regimen for the prevention of vascular disease among high risk individuals with type 2 diabetes mellitus.	The George Institute for Global Health, Sydney, Australia	Prof Dato’ Dr Khalid Yusoff			2011-2014	https://clinicaltrials.gov/ct2/show/NCT00949286
	BREATH 3082	A 12-month, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Reslizumab (3.0 mg/kg) in the reduction of clinical asthma exacerbations and change in lung function in patients (12-75 years of age) with eosinophilic asthma.	Cephalon Inc	AP Dr Tengku Saifudin Tengku Ismail	1)Dr Wan Haniza 2)Dr Ahmad Izuanuddin 3)Dr Mohd Arif Mohd Zim 4)Dr. Siti Kamariah Othman		2011-2014	https://clinicaltrials.gov/ct2/show/NCT01287039
	TAK-875 or GRAND Study	A Multicenter, randomized, Double Blind, Placebo Controlled, Study to Evaluate CV outcomes of TAK-875 50 mg in Addition to standard of Care in Subjects with T2DM and with CVD or Multiple Risk Factors for CV Events	TAKEDA Global USA	Prof Dato’ Dr Khalid Yusoff	1)Assoc Prof Dr Sazzli Sahlan Kasim 2)Dr Effarezan Abdul Rahman 3)Dr. Mohd Kamal Mohd Arshad 4)Dr. Hafisyatul Aiza		2013-2014	https://clinicaltrials.gov/ct2/show/NCT01609582
	CQMF149F2202	A randomized, double-blind, 12-week treatment, parallelgroup study to evaluate the efficacy and safety of QMF149 (150 μg/160 μg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 μg/500 μg b.i.d.) in patients with chronic obstructive pulmonary disease.	Novartis	AP Dr Tengku Saifudin Tengku Ismail	1)Dr Ahmad Izuanuddin 2)Dr Mohd Arif Mohd Zim		2013-2014	https://clinicaltrials.gov/ct2/show/NCT01636076
	HOPE-4 RAPID APPRAISAL	Multi-Method Health System (Rapid Appraisal)	PHRI	Prof Dato Dr Khalid Yusoff	Dr Ng Kien Keat	SMC: Fadhlina Ab Majid SC: 1) Nurshamin Ghazali 2)Naimah 3) Emilia	2012-2014
	HOPE-3	Heart Outcomes Prevention Evaluation-3	PHRI	Prof Dato Dr Khalid Yusoff	Dr. Effarezan Abdul Rahman	SMC: Syumaimah Muhamad Yunus	2007-2015	https://www.phri.ca/research/hope-3
	C-SCADE 8	A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety of BI 10773 (10mg and 25mg administered orally once daily) compared to usual care in Type2 diabetes mellitus patients with increased risk	Boehringer Ingelhem	AP Dr Rohana Abdul Ghani	Dr Ahmad Izuanuddin Ismail	Vickyneswary Muniandy	2010-2015	https://clinicaltrials.gov/ct2/show/NCT01131676
	INTER-CHF SG BULOH	An international registry to study the current causes, treatment, barriers to care, and outcome of heart failure in Africa, Asia and South America	PHRI	National PI Prof Dato Dr Khalid Yusoff UiTM Sg Buloh PI AP Dr Sazzli Shahlan Kasim	Dr.Johan Rizwal Ismail	SMC: Sazreza Shahadan SC: Nuaim Hussin	2012-2015	https://www.phri.ca/research/inter-chf
	INTER-CHF SELAYANG	An international registry to study the current causes, treatment, barriers to care, and outcome of heart failure in Africa, Asia and South America	PHRI	Prof Dato Dr Khalid Yusoff	1) Dr.Hafisyatul Aiza 2)Dr.Lim Chiao Wen	SMC: Sazreza Shahadan SC: Saleha Baharuddin	2012-2015	https://www.phri.ca/research/inter-chf
	AUSTRI SG BULOH	A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.	GlaxoSmithKline Research & Development Limited	Dr Faisal Mohd Fadzli	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3) Dr Siti Kamariah Othman	SMC: Irda Yasmoon Awang SC: Nurnadiah Nordin	2012-2015	https://www.clinicaltrials.gov/ct2/show/NCT01475721
	AUSTRI SELAYANG	A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.	GlaxoSmithKline Research & Development Limited	Dr Ahmad Izuanuddin Ismail	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3) Dr Siti Kamariah Othman	SMC: Irda Yasmoon Awang SC: Nur Asimah Zainal Abidin	2012-2015	https://www.clinicaltrials.gov/ct2/show/NCT01475721
	VESTRI	A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Paediatric Subjects with Asthma.	GlaxoSmithKline Research & Development Limited	Dr Faisal Mohd Fadzli	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3) Dr Siti Kamariah Othman	Nurnadiah Nordin	2012-2015	https://clinicaltrials.gov/ct2/show/NCT01462344
	BREATH 3085	An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Cephalon-Sponsored Study in Eosinophilic Asthma	Cephalon Inc	AP Dr Tengku Saifudin Tengku Ismail	1)Dr Ahmad Izuanuddin 2)Dr Mohd Arif Mohd Zim		2012-2015	https://clinicaltrials.gov/ct2/show/NCT01290887
	ROFLUMILAST	A 52-week, Double-blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500µg on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Treated with a Fixed Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)	Forest Research Institute, Inc	Dr Ahmad Izuanuddin Ismail	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3)Dr. Siti Kamariah Othman	1)Irda Yasmoon Awang 2)Nur Asimah Zainal Abidin	2012-2015	https://www.mayo.edu/research/clinical-trials/cls-20112131
	SUMMIT	A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease	GlaxoSmithKline Research & Development Limited	Dr Ahmad Izuanuddin Ismail	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3)Dr. Siti Kamariah Othman 4)Dr Nurul Yaqeen Mohd Esa	1)Irda Yasmoon Awang 2)Nur Asimah Zainal Abidin	2014-2015	https://clinicaltrials.gov/ct2/show/NCT01313676
	CNTO	A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease	Janssen Research & development,LLC	Dr Ahmad Izuanuddin Ismail	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3)Dr. Siti Kamariah Othman 4)Dr Nurul Yaqeen Mohd Esa	1)Nurnadiah Nordin 2)Nur Asimah Zainal Abidin 3)Irda Yasmoon Awang	2014-2015	https://clinicaltrials.gov/ct2/show/NCT01966549
	SOLITAIRE	A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia	Chempra Pharmaceutical	Dr Ahmad Izuanuddin Ismail	1)Assoc Prof Dr Tengku Saifudin Tengku Ismail 2)Dr Mohd Arif Mohd Zim 3)Dr. Siti Kamariah Othman 4)Dr Nurul Yaqeen Mohd Esa	1)Nur Asimah Zainal Abidin 2)Nur Nadiah Nordin	2014-2015	https://www.clinicaltrials.gov/ct2/show/NCT01968733
	CRLX030A2302 RELAX ASIA	A Multi center, randomized, double-blind, placebo controlled phase III study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patients.	Novartis	AP Dr Sazzli Shahlan Kasim	1)Dr.Johan Rizwal Ismail 2) Dr Mohd Kamal Mohd Arshad 3)Dr Hafisyatul Aiza Zainal Abidin 4)Dr Nicholas Chua Yul Chye 5)Dr Effarezan Abdul Rahman 6)Dr Zubin Othman Ibrahim 7)Dr Rizmy Najme Khair	1) Siti Masnirah Alwi 2)Nuaim Hussin	2013-2016	https://clinicaltrials.gov/ct2/show/NCT01870778
	MASCOT Registry	Multinational Abluminal Sirolimus Coated BiO-Engineered StenT –The MASCOT Post Marketing Registry	Orbus-Neich Medical Inc.	AP Dr Sazzli Shahlan Kasim	1)Dr.Johan Rizwal Ismail 2) Dr Mohd Kamal Mohd Arsha 3)Dr Hafisyatul Aiza Zainal Abidin 4) Dr. Lim Chiao Wen 5)Dr Rizmy Najme Khair 6)Dr Effarezan Abdul Rahman 7)Dr Nicholas Chua Yul Chye	Zureena Rahim	2015 – 2016.	https://clinicaltrials.gov/ct2/show/NCT02183454
	QUALIFY	Quality of adherence to guideline recommendations for life-saving treatment in heart failure: an national survey, "QUALIFY Registry”	Novatech	AP Dr Sazzli Shahlan Kasim	1)Dr.Johan Rizwal Ismail 2) Dr Mohd Kamal Mohd Arshad	Siti Masnirah Alwi	2014-2017
	CANVAS-R	CaNagliflozin cardioVascular Assessment Study-Renal A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with Type 2 Diabetes Mellitus	Janssen Research & development,LLC	Prof Dato Dr Khalid Yusoff	Dr.Rizmy Najme Khir	1)Sazreza Shahadan 2)Saleha Baharuddin	2014-2017	https://clinicaltrials.gov/ct2/show/NCT01989754
	COROFLEX ISAR INTERNATIONAL REGISTRY	Coroflex Isar International Registry is to assess the safety and efficacy of elective deploument of the Sirolimus-eluting Coroflex ISARTM Stent in the treatment of ‘real world’ de-novo and restenotic lesions after stand-alone angioplasty in coronary arteries	B.Braun Medical Supplies Sdn Bhd	AP Dr Sazzli Shahlan Kasim	1)Dr.Johan Rizwal Ismail 2) Dr Mohd Kamal Mohd Arshad 3)Dr Hafisyatul Aiza Zainal Abidin 4) Dr. Lim Chiao Wen	Siti Masnirah Alwi	2015-2017	https://clinicaltrials.gov/ct2/show/NCT02629575
	DPNP	An Asian.Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of DS-5565 in patients withDiabetic Peripheral Neuropathic Pain followed by a 52-Week Open-Label Extension - (DPNP)	Daiichi Sankyo	AP Dr Rohana Abdul Ghani	Dr.Annamalai Chandramouli		2015 - 2017	https://clinicaltrials.gov/ct2/show/NCT02318706
	RECOPD	Risk Factor of Recurrent Exacerbation	Malaysian Thoracic Society	Dr Ahmad Izuanuddin Ismail	1)Dr Mohd Arif Mohd Zim 2)Dr Muhamad Amin 3)Dr Nurul Yaqeen Mohd Esa 4)Dr Lily Diana 5)Dr Aisya Natasya Musa 6) Dr Siti Kamariah Othman	1) Nur Nadiah Nordin 2)Nurul Suhada binti Kamaruddin	2012-2018
	ODYSSEY (SG BULOH)	Phase III study which is a randomized, double blind, placebo controlled, parallel group study to evaluate the effect of study drug on the occurrence of CV events in patients who have recently experience an ACS (EFC11570) Drug SAR236553	Sanofi Aventis R&D	National PI Prof Dato Dr Khalid Yusoff UiTM Sg Buloh PI AP Dr Sazzli Shahlan Kasim	1)Dr Johan Rizwal Ismail 2)Dr Mohd Kamal Mohd Arshad 3) Dr Zubin Othman Ibrahim 4)Dr Nicholas Chua Yul Chye	1) Nurhasanah Abdul Rahman 2) Siti Masnirah Alwi	2013-2018	https://clinicaltrials.gov/ct2/show/NCT01663402
	ODYSSEY (SELAYANG)	Phase III study which is a randomized, double blind, placebo controlled, parallel group study to evaluate the effect of study drug on the occurrence of CV events in patients who have recently experience an ACS (EFC11570) Drug SAR236553	Sanofi Aventis R&D	National PI Prof Dato Dr Khalid Yusoff UiTM Selayang PI Dr Hafisyatul Aiza Zainal Abidin	Dr Effarezan Abdul Rahman	SMC: Noor Amanina Shaharudin SC: 1)Syuhaida Sulaiman 2) Zainol Ariffin Mohammad	2013-2018	https://clinicaltrials.gov/ct2/show/NCT01663402
	mySTEMI	Malaysia ST-Elevation Myocardial Infarction (MySTEMI) Network Program	National Heart Association of Malaysia	Dr Mohd Kamal Mohd Arshad	1) Assoc Prof Sazli Kasim 2)Dr Johan Rizwal Ismail 3 )Dr Nicholas Chua Yul Chye	1)Siti Masnirah Alwi 2)Nurhasanah Abdul Rahman	2016-2018	https://www.clinicaltrials.gov/ct2/show/NCT02597920
	Pradaxa	Non-interventional study describing patients´ perception on anticoagulant treatment and treatment convenience when treated with Pradaxa® or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation.	Boehringer Ingreihm	Dr Zubin Othman Ibrahim	1) Assoc Prof Sazli Kasim 2)Dr Johan Rizwal Ismail 3)Dr Nicholas Chua Yul Chye	Siti Masnirah Alwi	2016-2018
	HAVE	Hormonal Abnormalities Amongst HIV-Infected Individuals (HAVE) Horm (one-off study)	Initiated Study (LESTARI)	AP Dr Rohana Abdul Ghani	Dr Rosdina	Nur Atikah Bt Dolah	2016-2018
	EDIFIED	The Effects of Dapagliflozin (SGLT-2 Inhibitor) on Endothelial Dysfunction in Type 2 Diabetes Mellitus	Astra Zeneca (Malaysia)	AP Dr Rohana Abdul Ghani	Dr Nor Aisyah Zainordin	Fatin Aqilah Abu Yazid	2016-2018
	METABOLOMIC	Metabolomic Profiling in Type 2 Diabetes Mellitus Patients in UiTM Medical Centre	Investigator Initiated Study (BESTARI)	AP Dr Rohana Abdul Ghani	Dr Fatimah Zaherah Mohamed Shah	Fatin Aqilah Abu Yazid	2016-2018
	EMBRACE	EMBRACE (Empagliflozin-Obtaining real health care data)	Boehringer Ingelheim (Malaysia) Sdn Bhd	AP Dr Rohana Abdul Ghani		Nur Atikah Bt Dolah	2017-2018
	MASKID	The Effectiveness of Mangosteen Skin Product (Spray8) on Diabetic Wound Healing	Furley Bioextract Sdn Bhd & Platcom Venture	Dr Wan Najwa Binti Wan Mohd Zohdi	Dr Nor Faridah Binti Ahmad Roslan	Nur Faridah Yusof	2018 (terminated)
	HOPE-4 STUDY	Heart Outcomes Prevention and Evaluation: HOPE-4	CIHR & Grand Challenges Canada as part of the Global Alliance for Chronic Disease	National PI Prof Dato Dr Khalid Yusoff UiTM Sg Buloh PI Dr Khairul Shafiq		SMC: Fadhlina Ab Majid SC: 1) Mardhiah Binti Baharom 2) Noor Azziana Binti Ismail 3) Nurul Shafiqah Mat Nor	2015-2019	https://www.phri.ca/research/hope-4
	COMPASS SG BULOH	A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major CV events in Patients with Coronary or Peripheral Artery Disease (COMPASS- CV OutcoMes for People using Anticoagulation StrategieS)	Bayer & PHRI	National PI Prof Dato Dr Khalid Yusoff UiTM Sg Buloh PI AP Dr Sazzli Shahlan Kasim	1)Dr.Johan Rizwal Ismail 2)Dr Mohd Kamal Mohd Arshad 3)Dr Nicholas Chua Yul Chye 4) Dr Zubin Othman Ibrahim	SMC: Sazreza Shahadan SC: Siti Masnirah Alwi	2014-2019	https://www.phri.ca/research/compass
	COMPASS SELAYANG	A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major CV events in Patients with Coronary or Peripheral Artery Disease (COMPASS- CV OutcoMes for People using Anticoagulation StrategieS)	Bayer & PHRI	National PI Prof Dato Dr Khalid Yusoff	1) Dr.Rizmy Najme Khir 2) Dr.Lim Chiao Wen	SMC: Sazreza Shahadan SC: Saleha Baharuddin	2014-2019	https://www.phri.ca/research/compass
	EXCSEL	A randomized placebo controlled in clinical trial to evaluate cardiovascular outcome after treatment with Exenatide once weekly in patient with Type 2 diabetes mellitus.	Astrazeneca	Prof Dr Rohana Abdul Ghani		Fatin Aqilah Abu Yazid	2014-2019
	HOPE 3 - Passive Follow-up	Heart Outcome Prevention Evaluation 3 - Passive Follow-up	PHRI	National PI Academician Emeritus Prof Dato Dr Khalid Yusoff UiTM PI Dr.Mazapuspavina Mat Yasin		Nornajwa Syakira Naem	2015-2019	https://www.phri.ca/research/hope-3-passive-follow-up
	VICTORIA	A randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF) - Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction	Merck, Sharp & Dohme (M) Sdn Bhd	Dr Hafisyatul Aiza Zainal Abidin	1)Assoc Prof Sazzli Kasim 2)Dr Rizmy Najme Khir 3)Dr Khairul Syafiq Ibrahim 4)Dr Ahmad Bakhtiar Md Radzi	1) Nurhasanah Abdul Rahman 2) Siti Masnirah Alwi	2016-2019	https://clinicaltrials.gov/ct2/show/NCT02861534
	INFLUENZA	1 year Hospital based surveillance for influenza cases in chronic obstructive pulmonary disease, asthmatic and community acquired pneumonia adult patients in Malaysia	Sanofi Pasteur	AP Dr Ahmad Izuanuddin Ismail	1) Dr. Mohd Arif Mohd Zim 2) Dr. Nurul Yaqeen Mohd Esa 3) Dr. Muhammad Amin Ibrahim 4) Dr. Aisya Natasya Musa	SMC: 1)Sazreza Shahadan 2)Irda Yasmoon Awang SC: 1) Siti Mukhaiyarah bt Mahtar 2)Nurnadiah Nordin	2018-2019
	CORRECT	Phenotyping COPD patients using specific COPD Assessment Tool Scores	UiTM Geran Lestari	Dr. Aisya Natasya Musa	Dr. Muhammad Amin Ibrahim	1)Irda Yasmoon Awang 2) Siti Mukhaiyarah bt Mahtar 3)Nurnadiah Nordin	Jul 2018-Dec 2019
	CHRONIC COUGH (MK7264-030)	A phase 3, randomized, double, placebo-controlled twelve months study to evaluate the efficacy and safety of MK-7264 in adult participants with chronic cough.	MSD	AP Dr Ahmad Izuanuddin Ismail	1) Dr. Mohd Arif Mohd Zim 2) Dr. Nurul Yaqeen Mohd Esa 3) Dr. Muhammad Amin Ibrahim 4) Dr. Aisya Natasya Musa	1) Siti Mukhaiyarah bt Mahtar 2)Nurnadiah Nordin	May 2019	https://clinicaltrials.gov/ct2/show/NCT03449147
	CAIN	A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis comorbidity	Novartis	Dr Tarita Taib	1) Dr W. Syameen Amira 2) Dr Nurashikin Ahmad 3)Dr Meera A/P Kupusamy	Irda Yasmoon Awang	Feb 2017-Jun 2019	https://clinicaltrials.gov/ct2/show/NCT0306660
	CREDENCE	A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter study of effect of Canagligflozin on renal and cardiovascular outcomes in subject which Type 2 Diabetes Mellitus and diabetic nephropathy	Janssen Research & development,LLC	Assoc Prof Dr Rohana Ghani			2015-2017	https://clinicaltrials.gov/ct2/show/NCT02065791
	INFLUENZA	1 year Hospital based surveillance for influenza cases in chronic obstructive pulmonary disease, asthmatic and community acquired pneumonia adult patients in Malaysia	Sanofi Pasteur	AP Dr Ahmad Izuanuddin Ismail	1) Dr. Mohd Arif Mohd Zim 2) Dr. Nurul Yaqeen Mohd Esa 3) Dr. Muhammad Amin Ibrahim 4) Dr. Aisya Natasya Musa	SMC: 1)Sazreza Shahadan 2)Irda Yasmoon Awang SC: 1) Siti Mukhaiyarah bt Mahtar 2)Nurnadiah Nordin	Jul 2018-Jan 2020
	SABINA	An observational, multi-country, cross sectional study describing SABA prescription and potential effects among asthma patients, using real-time electronic data collection methods in local health care settings	AstraZeneca	Dr Mohd Arif Mohd Zim	1)AP Dr Ahmad Izuanuddin Ismail 2)Dr Muhammad Amin Ibrahim 3)Dr Aisya Natasya Musa	SC: 1)Nurnadiah Nordin 2) Siti Mukhaiyarah bt Mahtar	Oct 2019-2021	https://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=25825
	Global Aware	GLOBAL AWARE – Emerging Markets (EM) (Adults With Atopic Dermatitis Reporting on Their Experience in Emerging Markets)	Sanofi Aventis	Dr Tarita Taib	1) Dr Meera A/P Kupusamy 2) Dr Liyana Dhamirah Aminuddin 3) Dr Sabrina Ab Wahab	Irda Yasmoon Awang	Dec 2019-Dec 2020

Research Grant

NO.

STUDY

PROTOCOL

SPONSOR

PI

CO-PI

TEAM STUDY

DURATION

STUDY LINK

QUICKLINKS

Follow Us on FB

C.E.N.T.R.E Sg Buloh

C.E.N.T.R.E Hospital Al-Sultan Abdullah

Main Menu